E. Testa

878 total citations
17 papers, 601 citations indexed

About

E. Testa is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, E. Testa has authored 17 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Surgery and 7 papers in Oncology. Recurrent topics in E. Testa's work include Gastric Cancer Management and Outcomes (9 papers), Colorectal Cancer Treatments and Studies (6 papers) and Metastasis and carcinoma case studies (3 papers). E. Testa is often cited by papers focused on Gastric Cancer Management and Outcomes (9 papers), Colorectal Cancer Treatments and Studies (6 papers) and Metastasis and carcinoma case studies (3 papers). E. Testa collaborates with scholars based in Italy, United Kingdom and New Zealand. E. Testa's co-authors include Francesco Graziano, Vincenzo Catalano, Stefano Cascinu, Anna Maria Baldelli, Paolo Giordani, Giuseppina Catalano, Daniele Santini, Paolo Alessandroni, Massimo Terzolo and Luigi Dogliotti and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and British Journal of Cancer.

In The Last Decade

E. Testa

17 papers receiving 583 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Testa Italy 12 304 284 237 95 83 17 601
Jung Wook Park United States 11 284 0.9× 166 0.6× 246 1.0× 68 0.7× 55 0.7× 22 662
Kazuho Imanaka Japan 14 306 1.0× 242 0.9× 171 0.7× 134 1.4× 77 0.9× 29 901
Chi‐Young Jeong South Korea 20 412 1.4× 446 1.6× 393 1.7× 212 2.2× 147 1.8× 58 1.1k
Kazuma Fujimoto Japan 15 563 1.9× 363 1.3× 183 0.8× 101 1.1× 59 0.7× 49 1.0k
Hiroshi Sonoue Japan 13 175 0.6× 222 0.8× 257 1.1× 118 1.2× 68 0.8× 26 588
M. Lichinitser United States 12 403 1.3× 623 2.2× 677 2.9× 146 1.5× 75 0.9× 23 1.3k
Kate Sumpter United Kingdom 13 483 1.6× 427 1.5× 381 1.6× 108 1.1× 99 1.2× 24 1.2k
Wen-hua Zhan China 14 179 0.6× 215 0.8× 234 1.0× 165 1.7× 69 0.8× 47 606
Łukasz Liszka Poland 13 106 0.3× 174 0.6× 159 0.7× 58 0.6× 38 0.5× 39 423
Dieter Köberle Switzerland 13 413 1.4× 255 0.9× 435 1.8× 99 1.0× 124 1.5× 23 781

Countries citing papers authored by E. Testa

Since Specialization
Citations

This map shows the geographic impact of E. Testa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Testa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Testa more than expected).

Fields of papers citing papers by E. Testa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Testa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Testa. The network helps show where E. Testa may publish in the future.

Co-authorship network of co-authors of E. Testa

This figure shows the co-authorship network connecting the top 25 collaborators of E. Testa. A scholar is included among the top collaborators of E. Testa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Testa. E. Testa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Chaudhary, Mohammad A., Yong Yuan, N. Varol, et al.. (2021). MO01.02 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States. Journal of Thoracic Oncology. 16(1). S15–S16. 1 indexed citations
2.
Calzà, Laura, et al.. (2018). Soy Intake and Breast Cancer. Journal of Health & Medical Informatics. 9(3). 1 indexed citations
3.
Spada, Daniele, Marzia Del Re, Valentina Citi, et al.. (2014). Liquid Biopsy to Monitor the Evolution of Nsclc Egfr+During Treatment with Gefintinib. Annals of Oncology. 25. iv559–iv559. 1 indexed citations
4.
Catalano, Vincenzo, Francesco Graziano, Daniele Santini, et al.. (2008). Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?. British Journal of Cancer. 99(9). 1402–1407. 72 indexed citations
5.
Santini, Daniele, Francesco Graziano, Vincenzo Catalano, et al.. (2006). Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer. 6(1). 125–125. 28 indexed citations
6.
Ruzzo, Annamaria, Francesco Graziano, Francesca Pizzagalli, et al.. (2005). Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Annals of Oncology. 16(6). 887–892. 59 indexed citations
7.
Scartozzi, Mario, Gennaro Galizia, Francesco Graziano, et al.. (2005). Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. British Journal of Cancer. 92(6). 1051–1054. 14 indexed citations
8.
Graziano, Francesco, Annamaria Ruzzo, Alessandra Mandolesi, et al.. (2004). Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Annals of Oncology. 15(3). 489–492. 43 indexed citations
9.
Santini, Daniele, Francesco Graziano, Vincenzo Catalano, et al.. (2004). Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC). Journal of Clinical Oncology. 22(14_suppl). 4237–4237. 2 indexed citations
10.
Mattioli, Rodolfo, P. Lippe, Cristian Massacesi, et al.. (2004). Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial.. PubMed. 24(5B). 3257–61. 12 indexed citations
11.
Santini, Daniele, Francesco Graziano, Vincenzo Catalano, et al.. (2004). Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC). Journal of Clinical Oncology. 22(14_suppl). 4237–4237. 1 indexed citations
12.
Graziano, Francesco, Daniele Santini, E. Testa, et al.. (2003). A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. British Journal of Cancer. 89(8). 1428–1432. 17 indexed citations
13.
Muretto, Pietro, Francesco Graziano, Maria Pia Staccioli, et al.. (2002). An endogastric capsule for measuring tumor markers ingastric juice: an evaluation of the safety and efficacy of a new diagnostic tool. Annals of Oncology. 14(1). 105–109. 20 indexed citations
14.
Graziano, Francesco, Renato Bisonni, Vincenzo Catalano, et al.. (2002). Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. British Journal of Cancer. 86(12). 1854–1857. 77 indexed citations
15.
Graziano, Francesco, Vincenzo Catalano, Anna Maria Baldelli, et al.. (2000). A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Annals of Oncology. 11(10). 1263–1266. 77 indexed citations
16.
Terzolo, Massimo, Anna Pia, Alfredo Berruti, et al.. (2000). Low-Dose Monitored Mitotane Treatment Achieves the Therapeutic Range with Manageable Side Effects in Patients with Adrenocortical Cancer1. The Journal of Clinical Endocrinology & Metabolism. 85(6). 2234–2238. 88 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jung Wook Park Breakdown of academic impact, for papers by Kazuho Imanaka Breakdown of academic impact, for papers by Chi‐Young Jeong Breakdown of academic impact, for papers by Kazuma Fujimoto Breakdown of academic impact, for papers by Hiroshi Sonoue Breakdown of academic impact, for papers by M. Lichinitser Breakdown of academic impact, for papers by Kate Sumpter Breakdown of academic impact, for papers by Wen-hua Zhan Breakdown of academic impact, for papers by Łukasz Liszka Breakdown of academic impact, for papers by Dieter Köberle
Rankless by CCL
2026